Answers are grounded in this paper and cite their sources.
studies across certain cancer types, heterogeneity among blueberry preparations, and pharmacokinetic constraints related to bioavailability remain significant limitations. Collectively, current evidence reflects early-stage preclinical findings that suggest that blueberry constituents represent a source of promising bioactive compounds. However, future clinical trials are needed to confirm blueberry's role in reducing cancer risk and supporting cancer management.
No takes yet. Share an insight, caveat, or question.
Tummala et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: